On September 23, 2026, FIL Limited bought 2.80 million shares of GENSCRIPT BIO (01548) on the SEHK open market at an average of HKD 41.7798 per share, involving about HKD 116.79 million. This was an on-exchange active trade, a direct dealing in the secondary market.
Prior to the acquisition, FIL Limited's long position in GENSCRIPT BIO was 113.52 million shares, representing 4.98%; following the acquisition, the holding changed to 116.32 million shares, with the long position ratio rising to 5.1%.